

UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		ATTORNEY DOCKET NO.		
9/531,120	03/17/00	PREUSS		D	ARC	D:P-01912
_			¬	EXAMINER		
HM12/0312 FULBRIGHT & JAWORSKI LLP				EINSMANN,J		
OLBRIGHT @ .00 CONGRESS		T		ART	UNIT	PAPER NUMBER
UITE 2400 USTIN TX 78				1655 DATE MA	.II FD∙	9
		DAIL MA	03	7/12/01		

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

<i>j</i> *	Application No.	Applicant(s)						
Notice to Commit	09/531,120	PREUSS ET AL	,					
Notice to Comply	Examiner	Art Unit						
	Juliet C. Einsmann	1655						
NOTICE TO COMPLY WITH REQUIREMENTS			INING					
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES								
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).								
The nucleotide and/or amino acid sequence disclosure of for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.8		not comply with th	ne requirements					
1. This application clearly fails to comply with the requirected to the final rulemaking notice published at 5the effective filing date is on or after July 1, 1998, set 1998) and 1211 OG 82 (June 23, 1998).	5 FR 18230 (May 1, 1990), and 1	114 OG 29 (May	15, 1990). If					
2. This application does not contain, as a separate p required by 37 C.F.R. 1.821(c).	art of the disclosure on paper cop	y, a "Sequence L	isting" as					
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."								
5. The computer readable form that has been filed w unreadable as indicated on the attached CRF Disket submitted as required by 37 C.F.R. 1.825(d).	vith this application has been four te Problem Report. A Substitute	nd to be damaged computer readab	and/or le form must be					
6. The paper copy of the "Sequence Listing" is not the as required by 37 C.F.R. 1.821(e).	e same as the computer readable	e from of the "Seq	uence Listing"					
∇ 7. Other: The sequence listing is not in the proper for from the figure descriptions what the appropriate sequence A-D)	rmat for sequences beginning wit nce identifiers are for the recited s	h SEQ ID NO: 18 equences (figure	0. It is not clear s 15 A-B and 23					
Applicant Must Provide: An initial or substitute computer readable form (CRF or compact dis) copy of the "Sequence Listing".							
An initial or <u>substitute</u> paper copy of the "Sequence specification.	Listing", as well as an amendmen	t directing its entr	y into the					
A statement that the content of the paper and comp no new matter, as required by 37 C.F.R. 1.821(e) or 1.8	outer readable copies are the san 21(f) or 1.821(g) or 1.825(b) or 1.	ne and, where ap 825(d).	plicable, include					
For questions regarding compliance to these re	equirements, please contact	::						
For Rules Interpretation, call (703) 308-4216								
For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support	<u> </u>							
Technical Assistance	703-287-0200							
To Purchase PatentIn Software								

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.	
				EXAMINER	
			ART UNIT	PAPER	
				9	
			DATE MAILEI).	

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Applicant must comply with the requirements of the sequence rules (37 CFR 1.821 - 1.825) before the application can be examined under 35 U.S.C. §§ 131 and 132.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R.. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Juliet Einsmann whose telephone number is (703) 306-5824. The examiner can normally be reached on Monday through Thursday 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (703) 308-1152. The fax number for the organization where this application or proceeding is assigned is (703) 308-4242.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Juliet Einsmann Patent Examiner

W. Garyl Jones

Supervisory Patent Examiner Technology Center 1600

3/8/01